Advanced Biomed faces Nasdaq delisting over bid price

Advanced Biomed Inc. reported that it has failed to meet Nasdaq’s minimum bid price requirement of $1.00 per share by the January 14, 2026 compliance deadline.

Rhea-AI Filing Summary

Advanced Biomed Inc. reported that it has failed to meet Nasdaq’s minimum bid price requirement of $1.00 per share by the January 14, 2026 compliance deadline. Nasdaq staff has notified the company that its common stock is scheduled for delisting and trading suspension on January 27, 2026 unless the decision is reversed.

The company appealed the delisting notice on January 21, 2026, which temporarily stayed any suspension and the filing of a Form 25-NSE while a Nasdaq Hearings Panel reviews the case. Advanced Biomed plans to present a remediation plan, including a reverse stock split that stockholders approved on January 12, 2026 and that is expected to become effective on or after February 13, 2026. The company cautions that there is no assurance the Panel will allow continued listing or that it will regain compliance within any time period that may be granted.

Insights

Equity markets and listing standards analyst

Nasdaq delisting risk rises despite appeal and planned reverse split.

Advanced Biomed Inc. has not restored its share price to Nasdaq’s $1.00 minimum bid level by the end of its January 14, 2026 compliance window. Nasdaq staff has therefore moved to delist the stock from the Nasdaq Capital Market, with suspension scheduled for the market open on January 27, 2026, subject to review.

The company filed an appeal on January 21, 2026, which automatically stayed the suspension and Form 25-NSE while a Hearings Panel considers its case. Management plans to rely in part on a reverse stock split approved by shareholders on January 12, 2026, expected to take effect on or after February 13, 2026, to help restore the bid price.

Outcome now depends on the Panel’s decision and whether the company can demonstrate and sustain compliance with the minimum bid price requirement within any grace period the Panel may allow. The company explicitly warns there is no assurance of continued listing, underscoring the elevated risk around its Nasdaq status.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

FAQ

Why did Advanced Biomed Inc. (ADVB) receive a Nasdaq delisting notice?

Advanced Biomed Inc. received a Nasdaq delisting notice because the bid price of its common stock closed below the $1.00 per share minimum required under Nasdaq Listing Rule 5550(a)(2) and the company did not regain compliance by the January 14, 2026 deadline.

What deadline did ADVB have to regain compliance with Nasdaq’s minimum bid price?

Advanced Biomed had a 180-day compliance period, ending on January 14, 2026, to restore its common stock bid price to at least $1.00 per share in accordance with Nasdaq Listing Rule 5810(c)(3)(A).

When is Advanced Biomed’s stock scheduled to be suspended and delisted from Nasdaq?

Nasdaq staff has notified Advanced Biomed that its securities are scheduled to be suspended and delisted at the opening of business on January 27, 2026, unless the delisting decision is changed following the company’s appeal.

How has Advanced Biomed Inc. responded to the Nasdaq delisting determination?

On January 21, 2026, Advanced Biomed appealed the delisting determination by submitting a hearing request to a Nasdaq Hearings Panel, which stayed both the suspension of its securities and the filing of Form 25-NSE while the Panel considers the case.

What steps is ADVB planning to take to regain Nasdaq compliance?

Advanced Biomed plans to present a compliance plan to the Nasdaq Hearings Panel that includes a reverse stock split, which was approved by stockholders on January 12, 2026 and is expected to become effective on or after February 13, 2026.

Is there any guarantee that Advanced Biomed will remain listed on Nasdaq?

No. The company states that there can be no assurance the Nasdaq Hearings Panel will grant continued listing or that Advanced Biomed will be able to demonstrate compliance within any period of time the Panel may grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 05:00 PM Learn about SEC filing dates

false 0001941029 0001941029 2026-01-16 2026-01-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

January 16, 2026

Date of Report (Date of earliest event reported)

Advanced Biomed Inc.

(Exact name of Company as specified in its charter)

Nevada		001-42548		87-2177170
(State or other jurisdiction		(Commission File Number)		(IRS Employer
of Incorporation)				Identification Number)

No. 689-85 Xiaodong Road, Yongkang District

Tainan City, Taiwan

(Address of principal executive offices)

886-6-3121716

(Registrant’s telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		ADVB		The Nasdaq Stock Market LLC

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on July 18, 2025, Advanced Biomed Inc. (the “Company”) received a written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (the “Staff”) notifying the Company that the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a compliance period of 180 calendar days, or until January 14, 2026 (the “Compliance Period”), to regain compliance with the Minimum Bid Price Requirement.

The Company did not regain compliance with the Minimum Bid Price Requirement by January 14, 2026. Accordingly, by letter dated January 16, 2026, the Staff notified the Company that its securities would be scheduled for delisting from The Nasdaq Capital Market and suspended at the opening of business on January 27, 2026, unless the Company requested an appeal of this determination by January 23, 2026 before a Hearings Panel (the “Panel”).

On January 21, 2026, the Company appealed the Staff’s delisting determination by submitting a hearing request to the Panel, which stayed the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision. The Company expects to present to the Panel a plan intended to enable the Company to regain compliance with the Minimum Bid Price Requirement, including a reverse stock split approved by the Company’s stockholders on January 12, 2026, which is expected to become effective on or after February 13, 2026. However, there can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will be able to evidence compliance within any period of time that may be granted by the Panel.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements, including those related to the Company’s intent to regain compliance with the Nasdaq Stock Market LLC’s continued listing requirements. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those stated or implied. These risks are detailed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

1 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Advanced Biomed Inc.
Date: January 21, 2026	By:	/s/ Yi Lu
		Yi Lu
		Chief Executive Officer

2